Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: CTXR stock price vs BA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BA's multiple
Needs BA P/S.
Implied fair value · at CTXR's multiple
Needs CTXR P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CTXR FY 2022 (ended Sep 30, 2022) · BA FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Citius Pharmaceuticals, Inc. · implied price per share
Bear
$0.09
Base
$0.11
Bull
$0.13
THE BOEING COMPANY · implied price per share
Bear
-$29.03
Base
-$34.16
Bull
-$39.28
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.01x
9.92x
Net debt / EBITDA
Leverage against operating earnings
0.09x
5.75x
Cash and equivalents
Liquid reserves on the balance sheet
$4.25M
$29.40B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zomedica Corp.
CTXR vs ZOM
Aquestive Therapeutics, Inc.
CTXR vs AQST
ACADIA PHARMACEUTICALS INC
CTXR vs ACAD
AMGEN INC
CTXR vs AMGN
GILEAD SCIENCES, INC.
CTXR vs GILD
AbbVie Inc.
CTXR vs ABBV
LOCKHEED MARTIN CORP
CTXR vs LMT
NORTHROP GRUMMAN CORP /DE/
CTXR vs NOC
GENERAL DYNAMICS CORP
CTXR vs GD
TEXTRON INC
CTXR vs TXT
$1.00M
$54.10B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe CTXR can rapidly scale revenue and convert its negative margins into sustainable profitability, then only consider the name as a speculative turnaround; otherwise, the relative valuation data argues for avoiding it because BA-based implied price is $0.01 versus a current price of $0.58 and quality signals are weak.
The valuation gap is extreme on a relative basis: CTXR trades at 175.6x P/S and 139.4x EV/Revenue versus BA at 2.0x P/S and 2.3x EV/Revenue, yet BA-implied price is only $0.01, implying -98.5% downside from the current $0.58. The market is clearly not anchoring CTXR to BA-style valuation multiples, and the current price is already near the top of the historical band of $0.52 to $0.63.
Supporting Metrics
